Update on chymopapain.
Chemonucleolysis with chymopapain is accepted by many surgeons as a reasonable alternative to lumbar diskectomy for the treatment of lumbar disk disease. Approximately 70 to 75 per cent of carefully selected patients are successfully treated following this therapy, but extreme care must be exercised for precise needle placement and prompt and vigorous management of major allergic reactions. Methods to avoid major complications and their management, should they occur, are discussed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D000772:Anesthesia, Local; D002422:Causalgia / Q000139:chemically induced; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002917:Chymopapain / Q000009:adverse effects / Q000627:therapeutic use*; D004329:Droperidol; D010450:Endopeptidases / Q000627:therapeutic use*; D005283:Fentanyl; D006801:Humans; D007267:Injections; D007405:Intervertebral Disc Displacement / Q000188:drug therapy*; D002542:Intracranial Embolism and Thrombosis / Q000209:etiology; D008875:Middle Aged; D009458:Neuroleptanalgesia; D010264:Paraplegia / Q000139:chemically induced; D011292:Premedication
D010450:Endopeptidases; D002917:Chymopapain; D004329:Droperidol; D005283:Fentanyl